

Prasinezumab

Cat. No.:	HY-P99405
CAS No.:	1960462-19-4
Target:	α -synuclein
Pathway:	Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α -synuclein. Prasinezumab has the potential for Parkinson's disease research ^[1] .
In Vitro	Prasinezumab against an epitope in the carboxyl terminus of human α -synuclein. Prasinezumab binds to human aggregated α -synuclein with a high affinity and avidity ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Gennaro Pagano, et al. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. *Front Neurol.* 2021 Oct 1;12:705407.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA